CoChat
Sign Up
Cited by 72HIV Research and TreatmentHIV/AIDS drug development and treatmentinterferon and immune responses

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Multifaceted antiviral actions of APOBEC3 cytidine deaminases

Chiu, Ya-Lin, Greene, Warner C.·2006·Trends in Immunology
DOI 10.1016/j.it.2006.04.003
Open this paper in CoChat — free account

Abstract

To defend against external pathogens, metazoan organisms have evolved numerous defenses that generally fall within the innate and adaptive immune responses. Considerable effort continues to focus on developing a vaccine to manipulate the adaptive immune system to protect against or control HIV-1. However, recent advances in our understanding of the innate immune system have revealed that cells have a potent intrinsic antiretroviral defense in the form of APOBEC3G, which is a member of a larger family of cytidine deaminases that are active against HIV-1 and other retroviruses. Insights into how the action of A3G is circumvented by HIV-1 through the action of its Vif protein, and the surprising mechanisms by which A3G is regulated within the cell, offer exciting new opportunities for developing novel anti-HIV-1 therapies that exploit this intrinsic antiretroviral system.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.it.2006.04.003

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Cellular RNA polymerase II, along with various viral and host factors, also influences retroviral mutations, particularly in HIV-1.

    “However, cellular RNA polymerase II, along with various viral and host factors, also influences retroviral mutations, particularly in HIV-1 (O’Neil et al. 2002, Mangeat et al. 2003, Chiu and Greene 2006, Hughes 2015).”

    From Beyond reverse transcription: molecular mechanisms and emerging paradigms in retroviral replication (2026) · cites this paper as Chiu and Greene 2006

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 80

  1. Sheehy, 2002, Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein, Nature, 418, 646, 10.1038/nature00939 · DOI
  2. Mariani, 2003, Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif, Cell, 114, 21, 10.1016/S0092-8674(03)00515-4 · DOI
  3. Stopak, 2003, HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability, Mol. Cell, 12, 591, 10.1016/S1097-2765(03)00353-8 · DOI
  4. Yu, 2004, Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome, Nat. Struct. Mol. Biol., 11, 435, 10.1038/nsmb758 · DOI
  5. Lecossier, 2003, Hypermutation of HIV-1 DNA in the absence of the Vif protein, Science, 300, 1112, 10.1126/science.1083338 · DOI
  6. Harris, 2003, DNA deamination mediates innate immunity to retroviral infection, Cell, 113, 803, 10.1016/S0092-8674(03)00423-9 · DOI
  7. Zhang, 2003, The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA, Nature, 424, 94, 10.1038/nature01707 · DOI
  8. Schrofelbauer, 2005, Human immunodeficiency virus type 1 Vpr induces the degradation of the UNG and SMUG uracil-DNA glycosylases, J. Virol., 79, 10978, 10.1128/JVI.79.17.10978-10987.2005 · DOI
  9. Kaiser, 2006, Uracil DNA glycosylase is dispensable for human immunodeficiency virus type 1 replication and does not contribute to the antiviral effects of the cytidine deaminase Apobec3G, J. Virol., 80, 875, 10.1128/JVI.80.2.875-882.2006 · DOI
  10. Simon, 1998, Evidence for a newly discovered cellular anti-HIV-1 phenotype, Nat. Med., 4, 1397, 10.1038/3987 · DOI
  11. Madani, 1998, An endogenous inhibitor of human immunodeficiency virus in human lymphocytes is overcome by the viral Vif protein, J. Virol., 72, 10251, 10.1128/JVI.72.12.10251-10255.1998 · DOI
  12. Conticello, 2003, The Vif protein of HIV triggers degradation of the human antiretroviral DNA deaminase APOBEC3G, Curr. Biol., 13, 2009, 10.1016/j.cub.2003.10.034 · DOI
  13. Marin, 2003, HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation, Nat. Med., 9, 1398, 10.1038/nm946 · DOI
  14. Yu, 2003, Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex, Science, 302, 1056, 10.1126/science.1089591 · DOI
  15. Mehle, 2004, Vif overcomes the innate antiviral activity of APOBEC3G by promoting its degradation in the ubiquitin-proteasome pathway, J. Biol. Chem., 279, 7792, 10.1074/jbc.M313093200 · DOI
  16. Mehle, 2004, Phosphorylation of a novel SOCS-box regulates assembly of the HIV-1 Vif-Cul5 complex that promotes APOBEC3G degradation, Genes Dev., 18, 2861, 10.1101/gad.1249904 · DOI
  17. Yu, 2004, Selective assembly of HIV-1 Vif-Cul5-ElonginB-ElonginC E3 ubiquitin ligase complex through a novel SOCS box and upstream cysteines, Genes Dev., 18, 2867, 10.1101/gad.1250204 · DOI
  18. Luo, 2005, Primate lentiviral virion infectivity factors are substrate receptors that assemble with cullin 5–E3 ligase through a HCCH motif to suppress APOBEC3G, Proc. Natl. Acad. Sci. U. S. A., 102, 11444, 10.1073/pnas.0502440102 · DOI
  19. Sheehy, 2003, The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif, Nat. Med., 9, 1404, 10.1038/nm945 · DOI
  20. Bogerd, 2004, A single amino acid difference in the host APOBEC3G protein controls the primate species specificity of HIV type 1 virion infectivity factor, Proc. Natl. Acad. Sci. U. S. A., 101, 3770, 10.1073/pnas.0307713101 · DOI
  21. Mangeat, 2004, A single amino acid determinant governs the species-specific sensitivity of APOBEC3G to Vif action, J. Biol. Chem., 279, 14481, 10.1074/jbc.C400060200 · DOI
  22. Schrofelbauer, 2004, A single amino acid of APOBEC3G controls its species-specific interaction with virion infectivity factor (Vif), Proc. Natl. Acad. Sci. U. S. A., 101, 3927, 10.1073/pnas.0307132101 · DOI
  23. Xu, 2004, A single amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factor-induced depletion, Proc. Natl. Acad. Sci. U. S. A., 101, 5652, 10.1073/pnas.0400830101 · DOI
  24. Gaddis, 2004, Further investigation of simian immunodeficiency virus Vif function in human cells, J. Virol., 78, 12041, 10.1128/JVI.78.21.12041-12046.2004 · DOI
  25. Delebecque, 2006, Restriction of foamy viruses by APOBEC cytidine deaminases, J. Virol., 80, 605, 10.1128/JVI.80.2.605-614.2006 · DOI
  26. Lochelt, 2005, The antiretroviral activity of APOBEC3 is inhibited by the foamy virus accessory Bet protein, Proc. Natl. Acad. Sci. U. S. A., 102, 7982, 10.1073/pnas.0501445102 · DOI
  27. Russell, 2005, Foamy virus Bet proteins function as novel inhibitors of the APOBEC3 family of innate antiretroviral defense factors, J. Virol., 79, 8724, 10.1128/JVI.79.14.8724-8731.2005 · DOI
  28. Bishop, 2004, Cytidine deamination of retroviral DNA by diverse APOBEC proteins, Curr. Biol., 14, 1392, 10.1016/j.cub.2004.06.057 · DOI
  29. Liddament, 2004, APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo, Curr. Biol., 14, 1385, 10.1016/j.cub.2004.06.050 · DOI
  30. Zheng, 2004, Human APOBEC3F is another host factor that blocks human immunodeficiency virus type 1 replication, J. Virol., 78, 6073, 10.1128/JVI.78.11.6073-6076.2004 · DOI
  31. Wiegand, 2004, A second human antiretroviral factor, APOBEC3F, is suppressed by the HIV-1 and HIV-2 Vif proteins, EMBO J., 23, 2451, 10.1038/sj.emboj.7600246 · DOI
  32. Liu, 2005, Regulation of Apobec3F and human immunodeficiency virus type 1 Vif by Vif-Cul5-ElonB/C E3 ubiquitin ligase, J. Virol., 79, 9579, 10.1128/JVI.79.15.9579-9587.2005 · DOI
  33. Doehle, 2005, Human APOBEC3B is a potent inhibitor of HIV-1 infectivity and is resistant to HIV-1 Vif, Virology, 339, 281, 10.1016/j.virol.2005.06.005 · DOI
  34. Jarmuz, 2002, An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22, Genomics, 79, 285, 10.1006/geno.2002.6718 · DOI
  35. Tian, 2006, Differential requirement for conserved tryptophans in human immunodeficiency virus type 1 Vif for the selective suppression of APOBEC3G and APOBEC3F, J. Virol., 80, 3112, 10.1128/JVI.80.6.3112-3115.2006 · DOI
  36. Kao, 2004, Production of infectious human immunodeficiency virus type 1 does not require depletion of APOBEC3G from virus-producing cells, Retrovirology, 1, 27, 10.1186/1742-4690-1-27 · DOI
  37. Kao, 2003, The human immunodeficiency virus type 1 Vif protein reduces intracellular expression and inhibits packaging of APOBEC3G (CEM15), a cellular inhibitor of virus infectivity, J. Virol., 77, 11398, 10.1128/JVI.77.21.11398-11407.2003 · DOI
  38. Sakai, 2006, The Vif and Vpr accessory proteins independently cause HIV-1-induced T cell cytopathicity and cell cycle arrest, Proc. Natl. Acad. Sci. U. S. A., 103, 3369, 10.1073/pnas.0509417103 · DOI
  39. Kobayashi, 2004, APOBEC3G targets specific virus species, J. Virol., 78, 8238, 10.1128/JVI.78.15.8238-8244.2004 · DOI
  40. Doehle, 2005, Differential sensitivity of murine leukemia virus to APOBEC3-mediated inhibition is governed by virion exclusion, J. Virol., 79, 8201, 10.1128/JVI.79.13.8201-8207.2005 · DOI
  41. Langlois, 2005, Mutational comparison of the single-domained APOBEC3C and double-domained APOBEC3F/G anti-retroviral cytidine deaminases provides insight into their DNA target site specificities, Nucleic Acids Res., 33, 1913, 10.1093/nar/gki343 · DOI
  42. Hache, 2005, The retroviral hypermutation specificity of APOBEC3F and APOBEC3G is governed by the C-terminal DNA cytosine deaminase domain, J. Biol. Chem., 280, 10920, 10.1074/jbc.M500382200 · DOI
  43. Janini, 2001, Human immunodeficiency virus type 1 DNA sequences genetically damaged by hypermutation are often abundant in patient peripheral blood mononuclear cells and may be generated during near-simultaneous infection and activation of CD4+ T cells, J. Virol., 75, 7973, 10.1128/JVI.75.17.7973-7986.2001 · DOI
  44. Newman, 2005, Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity, Curr. Biol., 15, 166, 10.1016/j.cub.2004.12.068 · DOI
  45. Chiu, 2005, Cellular APOBEC3G restricts HIV-1 infection in resting CD4+ T cells, Nature, 435, 108, 10.1038/nature03493 · DOI
  46. Zack, 1990, HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure, Cell, 61, 213, 10.1016/0092-8674(90)90802-L · DOI · Paper page
  47. Stevenson, 1990, HIV-1 replication is controlled at the level of T cell activation and proviral integration, EMBO J., 9, 1551, 10.1002/j.1460-2075.1990.tb08274.x · DOI
  48. Neil, 2001, Postentry restriction to human immunodeficiency virus-based vector transduction in human monocytes, J. Virol., 75, 5448, 10.1128/JVI.75.12.5448-5456.2001 · DOI
  49. Triques, 2004, Characterization of restrictions to human immunodeficiency virus type 1 infection of monocytes, J. Virol., 78, 5523, 10.1128/JVI.78.10.5523-5527.2004 · DOI
  50. Kreisberg, J.F. et al. Endogenous factors enhance HIV infection of tissue naive CD4 T cells by stimulating high-molecular-mass APOBEC3G complex formation. J. Exp. Med. (in press)
  51. Turelli, 2004, Response to comment on ‘Inhibition of hepatitis B virus replication by APOBEC3G’, Science, 305, 1403B, 10.1126/science.1100464 · DOI
  52. Turelli, 2004, Inhibition of hepatitis B virus replication by APOBEC3G, Science, 303, 1829, 10.1126/science.1092066 · DOI
  53. Rosler, 2004, Comment on ‘Inhibition of hepatitis B virus replication by APOBEC3G’, Science, 305, 1403a, 10.1126/science.1100464 · DOI
  54. Suspene, 2005, Extensive editing of both hepatitis B virus DNA strands by APOBEC3 cytidine deaminases in vitro and in vivo, Proc. Natl. Acad. Sci. U. S. A., 102, 8321, 10.1073/pnas.0408223102 · DOI
  55. Noguchi, 2005, G to A hypermutation of hepatitis B virus, Hepatology, 41, 626, 10.1002/hep.20580 · DOI
  56. Sasada, 2005, APOBEC3G targets human T-cell leukemia virus type 1, Retrovirology, 2, 32, 10.1186/1742-4690-2-32 · DOI
  57. Mahieux, 2005, Extensive editing of a small fraction of human T-cell leukemia virus type 1 genomes by four APOBEC3 cytidine deaminases, J. Gen. Virol., 86, 2489, 10.1099/vir.0.80973-0 · DOI
  58. Navarro, 2005, Complementary function of the two catalytic domains of APOBEC3G, Virology, 333, 374, 10.1016/j.virol.2005.01.011 · DOI
  59. Zhang, 2004, Rapid evolution of primate antiviral enzyme APOBEC3G, Hum. Mol. Genet., 13, 1785, 10.1093/hmg/ddh183 · DOI
  60. Bogerd, 2006, APOBEC3A and APOBEC3B are potent inhibitors of LTR-retrotransposon function in human cells, Nucleic Acids Res., 34, 89, 10.1093/nar/gkj416 · DOI
  61. Esnault, 2005, APOBEC3G cytidine deaminase inhibits retrotransposition of endogenous retroviruses, Nature, 433, 430, 10.1038/nature03238 · DOI
  62. Dutko, 2005, Inhibition of a yeast LTR retrotransposon by human APOBEC3 cytidine deaminases, Curr. Biol., 15, 661, 10.1016/j.cub.2005.02.051 · DOI
  63. Schumacher, 2005, APOBEC3G hypermutates genomic DNA and inhibits Ty1 retrotransposition in yeast, Proc. Natl. Acad. Sci. U. S. A., 102, 9854, 10.1073/pnas.0501694102 · DOI
  64. Chen, 2006, APOBEC3A is a potent inhibitor of adeno-associated virus and retrotransposons, Curr. Biol., 16, 480, 10.1016/j.cub.2006.01.031 · DOI
  65. An, 2004, APOBEC3G genetic variants and their influence on the progression to AIDS, J. Virol., 78, 11070, 10.1128/JVI.78.20.11070-11076.2004 · DOI
  66. Do, 2005, Exhaustive genotyping of the CEM15 (APOBEC3G) gene and absence of association with AIDS progression in a French cohort, J. Infect. Dis., 191, 159, 10.1086/426826 · DOI
  67. Simon, 2005, Natural variation in Vif: differential impact on APOBEC3G/3F and a potential role in HIV-1 diversification, PLoS Pathog., 1, e6, 10.1371/journal.ppat.0010006 · DOI
  68. Rose, 2004, Transcriptional regulation of APOBEC3G, a cytidine deaminase that hypermutates human immunodeficiency virus, J. Biol. Chem., 279, 41744, 10.1074/jbc.M406760200 · DOI
  69. Peng, 2006, Induction of APOBEC3 family proteins, a defensive maneuver underlying interferon-induced anti-HIV-1 activity, J. Exp. Med., 203, 41, 10.1084/jem.20051512 · DOI
  70. Tanaka, 2006, Anti-viral protein APOBEC3G is induced by interferon-α stimulation in human hepatocytes, Biochem. Biophys. Res. Commun., 341, 314, 10.1016/j.bbrc.2005.12.192 · DOI
  71. Cen, 2004, The interaction between HIV-1 Gag and APOBEC3G, J. Biol. Chem., 279, 33177, 10.1074/jbc.M402062200 · DOI
  72. Luo, 2004, Amino-terminal region of the human immunodeficiency virus type 1 nucleocapsid is required for human APOBEC3G packaging, J. Virol., 78, 11841, 10.1128/JVI.78.21.11841-11852.2004 · DOI
  73. Yu, 2004, APOBEC3B and APOBEC3C are potent inhibitors of simian immunodeficiency virus replication, J. Biol. Chem., 279, 53379, 10.1074/jbc.M408802200 · DOI
  74. Cullen, 2006, Role and mechanism of action of the APOBEC3 family of antiretroviral resistance factors, J. Virol., 80, 1067, 10.1128/JVI.80.3.1067-1076.2006 · DOI
  75. Mangeat, 2005, Lentiviral vectors and antiretroviral intrinsic immunity, Hum. Gene Ther., 16, 913, 10.1089/hum.2005.16.913 · DOI
  76. Turelli, 2005, Editing at the crossroad of innate and adaptive immunity, Science, 307, 1061, 10.1126/science.1105964 · DOI
  77. Huthoff, 2005, Cytidine deamination and resistance to retroviral infection: towards a structural understanding of the APOBEC proteins, Virology, 334, 147, 10.1016/j.virol.2005.01.038 · DOI
  78. Stopak, 2005, Protecting APOBEC3G: a potential new target for HIV drug discovery, Curr. Opin. Investig. Drugs, 6, 141
  79. Harris, 2004, Retroviral restriction by APOBEC proteins, Nat. Rev. Immunol., 4, 868, 10.1038/nri1489 · DOI
  80. Chiu, 2006, APOBEC3 cytidine deaminases: distinct antiviral actions along the retroviral life cycle, J. Biol. Chem., 281, 8309, 10.1074/jbc.R500021200 · DOI

Cited by

Sorted by citations

Metadata

Authors
Chiu, Y.-L., & Greene, W. C.
Affiliations
University of California, San Francisco (US)
ORCID
Greene, Warner C.
Venue
Trends in Immunology
Publisher
Elsevier BV
Published
2006-06
Volume
27
Issue
6
Pages
291-297
ISSN
1471-4906 (ISSN-L)
DOI
10.1016/j.it.2006.04.003
OpenAlex
W2071103917
Cited by
72
References
2
Citations by year
2025: 5 · 2023: 2 · 2022: 1 · 2020: 2 · 2019: 1 · 2018: 4 · 2017: 2 · 2016: 2 · 2015: 2 · 2014: 1 · 2013: 1 · 2012: 7
FWCI
1.37
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Trends in Immunology (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health
  • National Institute of Allergy and Infectious Diseases (R01AI065329)
Topics
  • Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
  • Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
  • Life Sciences › Immunology and Microbiology › Immunology › interferon and immune responses
Keywords
APOBEC3G, cytidine deaminase, HIV-1, innate immunity, Vif protein, retroviral restriction factors, HIV-1 vaccine
MeSH terms
APOBEC-3G Deaminase, Animals, Cytidine Deaminase, Humans, Nucleoside Deaminases, Repressor Proteins, HIV-1, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review